Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Status:
Recruiting
Trial end date:
2022-10-03
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for
the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in
patients experiencing moderate to severe pruritus.